Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib

由 Onn, A, Tsuboi, M, Thatcher, N
出版 2004

L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients

由 Portal, D, Hofstetter, L, Eshed, I, Dan-Lantsman, C, Sella, T, Urban, D, Onn, A, Bar, J, Segal, G
發表在 Cancer Manag Res (2019)

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

由 Rodon, J., Soria, J. C., Berger, R., Batist, G., Tsimberidou, A., Bresson, C., Lee, J. J., Rubin, E., Onn, A., Schilsky, R. L., Miller, W. H., Eggermont, A. M., Mendelsohn, J., Lazar, V., Kurzrock, R.
發表在 Ann Oncol (2015)